Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Showing 1-25 of 31 citing articles:

Medications for Obesity
Kimberly A. Gudzune, Robert F. Kushner
JAMA (2024) Vol. 332, Iss. 7, pp. 571-571
Closed Access | Times Cited: 34
Neuropsychiatric adverse events associated with Glucagon-like peptide-1 receptor agonists: a pharmacovigilance analysis of the FDA Adverse Event Reporting System database
Wenchao Lu, Shihan Wang, Huilin Tang, et al.
European Psychiatry (2025) Vol. 68, Iss. 1
Open Access | Times Cited: 1
Association of glucagon-like peptide-1 receptor agonists with suicidal ideation and self-injury in individuals with diabetes and obesity: a propensity-weighted, population-based cohort study
Isabel Hurtado, Celia Robles, Salvador Peiró, et al.
Diabetologia (2024) Vol. 67, Iss. 11, pp. 2471-2480
Open Access | Times Cited: 8
Glucagon-Like Peptide-1 Receptor Agonists and Risk for Suicidal Ideation and Behaviors in U.S. Older Adults With Type 2 Diabetes
Huilin Tang, Ying Lü, William T. Donahoo, et al.
Annals of Internal Medicine (2024) Vol. 177, Iss. 8, pp. 1004-1015
Closed Access | Times Cited: 7
Association between glucagon‐like peptide‐1 receptor agonists and risk of suicidality: A comprehensive analysis of the global pharmacovigilance database
Tae Hyeon Kim, Kyeongmin Lee, Seoyoung Park, et al.
Diabetes Obesity and Metabolism (2024) Vol. 26, Iss. 11, pp. 5183-5191
Closed Access | Times Cited: 5
Antidepressants and Weight Gain: An Update on the Evidence and Clinical Implications
Lauren Moss, Marci Laudenslager, Kristine J. Steffen, et al.
Current Obesity Reports (2025) Vol. 14, Iss. 1
Closed Access
The Effect of Glucagon-Like Peptide-1 Receptor Agonists on Measures of Suicidality A Systematic Review
K.L. Valentino, Kayla M. Teopiz, William W. L. Cheung, et al.
Journal of Psychiatric Research (2025) Vol. 183, pp. 112-126
Open Access
GLP-1 agonists and risk of suicidal thoughts and behaviours: Confound by indication once again? A narrative review
Robertas Strumila, Aistė Lengvenytė, Sebastien Guillaume, et al.
European Neuropsychopharmacology (2024) Vol. 87, pp. 29-34
Open Access | Times Cited: 4
GLP-1 Receptor Agonists and Suicidality—Caution Is Needed
Francesco Salvo, Jean‐Luc Faillie
JAMA Network Open (2024) Vol. 7, Iss. 8, pp. e2423335-e2423335
Open Access | Times Cited: 4
Risk of Suicidal Ideation or Attempts in Adolescents With Obesity Treated With GLP1 Receptor Agonists
Liya Kerem, Joshua Stokar
JAMA Pediatrics (2024)
Closed Access | Times Cited: 4
Assessment of Riociguat-related adverse events: a disproportionality analysis utilizing the FDA adverse event reporting system database
Lingling Wang, Zhenyu Mao, Pengdou Zheng, et al.
Expert Opinion on Drug Safety (2025)
Closed Access
Association of GLP‐1 Receptor Agonists With Risk of Suicidal Ideation and Behaviour: A Systematic Review and Meta‐Analysis
Ganesh Bushi, Mahalaqua Nazli Khatib, Shivam Rohilla, et al.
Diabetes/Metabolism Research and Reviews (2025) Vol. 41, Iss. 2
Open Access
An analysis on the role of glucagon-like peptide-1 receptor agonists in cognitive and mental health disorders
Riccardo De Giorgi, Ana Ghenciulescu, Oliwia Dziwisz, et al.
Nature Mental Health (2025)
Open Access
Comprehensive analysis of adverse events associated with T-cell engagers using the FAERS database
Xiangyang Le, Yefu Zhang, Junlong Ma
Expert Opinion on Drug Safety (2025)
Closed Access
Exploring the potential association between stimulant or atomoxetine use and suicidal or self-injurious behaviors in children with attention deficit hyperactivity disorder: real-world insights from the FAERS database
Jinhua Liu, Liping Xue, Fanxiang Zeng, et al.
European Child & Adolescent Psychiatry (2025)
Closed Access
Pharmacotherapy of Weight‐loss and Obesity with a Focus on GLP 1‐Receptor Agonists
Merle Myerson, Rodis Paparodis
The Journal of Clinical Pharmacology (2024) Vol. 64, Iss. 10, pp. 1204-1221
Closed Access | Times Cited: 3
Pharmacovigilance study of GLP-1 receptor agonists for metabolic and nutritional adverse events
Long He, Qiuyu Li, Yongfeng Yang, et al.
Frontiers in Pharmacology (2024) Vol. 15
Open Access | Times Cited: 2
Risk of ophthalmic adverse drug reactions in patients prescribed glucagon-like peptide 1 receptor agonists: a pharmacovigilance study based on the FDA adverse event reporting system database
Jianxing Zhou, Wei Huang, Y. Xie, et al.
Endocrine (2024)
Closed Access | Times Cited: 2
Multiple Adverse Reactions Associated With the Use of Second-Generation Antipsychotics in People With Alzheimer’s Disease: A Pharmacovigilance Analysis Based on the FDA Adverse Event Reporting System
Jianxing Zhou, Zipeng Wei, Wei Huang, et al.
Annals of Pharmacotherapy (2024)
Closed Access | Times Cited: 1
Exploration of the Potential Association between Newer Antiseizure Medications and Arrhythmias: Integrating Pharmacovigilance and Bioinformatics Evidence
Jianxing Zhou, Zhenhui Chen, Mengjun Zhang, et al.
Seizure (2024) Vol. 123, pp. 26-33
Closed Access | Times Cited: 1
Glucagon-like peptide-1 receptor agonists and impaired gastric emptying: a pharmacovigilance analysis of the US Food and Drug Administration adverse event reporting system
Haoquan Huang, Chuwen Hu, Fan Liu, et al.
British Journal of Anaesthesia (2024)
Closed Access | Times Cited: 1
The safety profile of usage of glucagon‐like peptide‐1 receptor agonists in pregnancy: A pharmacovigilance analysis based on the Food and Drug Administration Adverse Event Reporting System
Jianxing Zhou, Zipeng Wei, Weipeng Lai, et al.
British Journal of Clinical Pharmacology (2024)
Closed Access | Times Cited: 1
Data mining study on adverse events of tirzepatide based on FAERS database
Yan Huo, Minghua Ma, Xiaolan Liao
Expert Opinion on Drug Safety (2024), pp. 1-9
Closed Access
Real-World Data in Pharmacovigilance Database Provides a New Perspective for Understanding the Psychiatric Adverse Events Associated with Glucagon-Like Peptide-1 Receptor Agonists (Glp-1 RAs) Exposure
Yao Yao, Lin Chen, Xiaohong Chen, et al.
(2024)
Closed Access
Mortality and Serious Adverse Events Associated With Glucagon-Like Peptide-1 Receptor Agonists: A Pharmacovigilance Study Using the FDA Adverse Event Reporting System
Mehul Bhattacharyya, Larry E. Miller, Anna L. Miller, et al.
Cureus (2024)
Open Access
Page 1 - Next Page

Scroll to top